

Financial Tear Sheet

Corporate Profile

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company's clinical development pipeline includes multiple hormone therapy products at various stages of clinical development. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites: vitamedmdrx.com and bocagreenmd.com .

Stock Performance

TXMD (Common Stock)

Exchange	NYSE (US Dollar)
Price	\$5.67
Change (%)	▼ 0.01 (0.18%)
Volume	558,090
52 Week Low	\$3.50
Market Cap	\$1,158,306,167
Rolling EPS	-0.46
PE Ratio	0
Shares Outstanding	203,927,142
Data as of 06/28/17 12:09 p.m. ET	



Recent Headlines & Events

- 05/23/17  
TherapeuticsMD Announces Presentation at Jefferies 2017 Healthcare Conference on June 8
- 05/10/17  
TherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
- 05/08/17  
TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/23/17	4
06/23/17	4
06/23/17	4
06/23/17	4

Corporate Governance

EXECUTIVE TEAM

Robert G. Finizio	Chief Executive Officer, Co-Founder, and Director
John Milligan	President
Dan Cartwright	Chief Financial Officer
Dawn Halkuff	Chief Commercial Officer
Yulii Bogatyrenko	Executive Vice President, Corporate Development

CLINICAL TEAM

Brian Bernick, M.D., F.A.C.O.G.	Co-Founder and Chief Clinical Officer
Sebastian Mirkin, M.D.	Chief Medical Officer
Julia Amadio	Chief Product Officer
Marlan Walker, J.D.	General Counsel
Christine Miller, Pharm.D.	Vice President of Regulatory Affairs

OPERATIONS TEAM

Mitchell Krassan	Chief Strategy Performance Officer
Jason Spitz	Vice President of Marketing
Christian Bloomgren	Vice President of Sales
Michael Donegan	Vice President of Finance

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	215	1,435.12	104.6	213,307,826
Mutual Fund	236	692.27	58.6	119,548,808
Insider *	4	123.08	10.0	20,418,978

\*Insider values reflect direct beneficial ownership.  
Data Provided by Thomson Reuters

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Fidelity Management & Research Company	28,656,231	14.1	-360,000	03/31/17
T. Rowe Price Associates, Inc.	25,572,286	12.5	1,909,090	03/31/17
Finizio (Robert G)	20,643,559	10.1	-145,000	04/17/17
The Boston Company Asset Management, LLC	17,842,794	8.8	-649,913	03/31/17
Franklin Advisers, Inc.	10,336,318	5.1	-860,459	03/31/17
BlackRock Institutional Trust Company, N.A.	10,230,508	5.0	98,338	03/31/17
Smith (Robert J)	10,056,770	4.9	2,199,265	04/17/17
The Vanguard Group, Inc.	9,801,870	4.8	515,992	03/31/17
Bernick (Brian A)	6,827,371	3.4	-101,128	04/17/17
JP Morgan Asset Management	6,744,870	3.3	243,446	03/31/17

Data provided by Nasdaq, Minimum 15 minutes delayed. View Attributions and Sources